| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6495162 | ANDRX LABS LLC | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US8475841 | ANDRX LABS LLC | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6099859 | ANDRX LABS LLC | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US7919116 | ANDRX LABS LLC | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6790459 | ANDRX LABS LLC | Methods for treating diabetes via administration of controlled release metformin |
Mar, 2021
(3 years ago) | |
| US6866866 | ANDRX LABS LLC | Controlled release metformin compositions |
Mar, 2021
(3 years ago) | |
Fortamet is owned by Andrx Labs Llc.
Fortamet contains Metformin Hydrochloride.
Fortamet has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Fortamet are:
- US6495162
- US8475841
- US6099859
- US7919116
- US6790459
- US6866866
Fortamet was authorised for market use on 27 April, 2004.
Fortamet is available in tablet, extended release;oral dosage forms.
Fortamet can be used as method of lowering blood glucose by once daily administration.
The generics of Fortamet are possible to be released after 17 March, 2021.
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 April, 2004
Treatment: Method of lowering blood glucose by once daily administration
Dosage: TABLET, EXTENDED RELEASE;ORAL
FORTAMET family patents
